| Followers | 0 |
| Posts | 6673 |
| Boards Moderated | 0 |
| Alias Born | 01/28/2011 |
Sunday, January 29, 2012 2:06:12 PM
I'm in since .011 and I'm not selling all year unless the company gives me a good reason to sell.
I know penny stocks. I know how to play them. I learned the hard way at first, but I'm thankful for lessons learned. That said, ATRN isn't your typical penny stock. This was (and will be again) a big board stock, run by big board executives who know how to run a profitable business and make money for themselves and their investors.
And if you want to teach me something, try not to put a past participle after "will." It's just a little distracting. :)
I know penny stocks. I know how to play them. I learned the hard way at first, but I'm thankful for lessons learned. That said, ATRN isn't your typical penny stock. This was (and will be again) a big board stock, run by big board executives who know how to run a profitable business and make money for themselves and their investors.
And if you want to teach me something, try not to put a past participle after "will." It's just a little distracting. :)
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
